Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | GCK | P35557 | 4/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1860437 | 1.00 | KCNH2 (0.47) | KCNH2GCKSLC6A3SCN9ASLC6A2 | |
| SCHEMBL1860441 | 1.00 | KCNH2 (0.47) | KCNH2GCKSLC6A3SCN9ASLC6A2 | |
| SCHEMBL1860435 | 1.00 | KCNH2 (0.47) | KCNH2GCKSLC6A3SCN9ASLC6A2 | |
| SCHEMBL1867444 | 0.89 | KCNH2 (0.47) | KCNH2GCKSLC6A3SCN9ASLC6A2 | |
| SCHEMBL1863778 | 0.89 | KCNH2 (0.47) | KCNH2GCKSCN9A | |
| SCHEMBL1859498 | 0.89 | KCNH2 (0.47) | KCNH2GCKSCN9A | |
| SCHEMBL2642340 | 0.89 | SLC6A3 (0.49) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL21882880 | 0.84 | KCNH2 (0.62) | KCNH2GCKSLC6A3SLC6A2SLC6A4 | |
| SCHEMBL2646278 | 0.84 | KCNH2 (0.62) | KCNH2GCKSLC6A3SLC6A2SLC6A4 | |
| SCHEMBL2641989 | 0.84 | KCNH2 (0.46) | KCNH2GCKSLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935699-B2 | Pyrazole glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2011-05-03 | — | — | US | disclosed |
| EP-2261216-A2 | Pyrazoles as glucokinase activators | F. Hoffmann-La Roche AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| EP-2046755-A2 | PYRAZOLES AS GLUCOKINASE ACTIVATORS | F. Hoffmann-Roche AG (CH) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008012227-A2 | PYRAZOLES AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-31 | — | — | WO | disclosed |
| US-20080021032-A1 | Pyrazole glucokinase activators | BERTHEL STEVEN JOSEPH | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021032-A1 | Pyrazole glucokinase activators | GCKR, GCK, GALK1 | KCNH2 2241/4885GCK 2/4885SLC6A3 3386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.